Taiga Biotechnologies, Inc. is a privately held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions. Each of the company's core programs derives from Taiga's proprietary technology platform for conditionally immortalized adult hematopoetic stem cells (HSCs). The companyâs initial focus includes the discovery and development of fully human therapeutic monoclonal antibodies against difficult protein targets, an immune response enhancer for improving vaccination strategies for infectious diseases and cancer, and the development of a universal donor blood stem cell line for clinical use
